Table 2.
Treatment regimens and outcomes for LTBI in 246 patients.
| LTBI treatment regimen | 3 HR | Total | P | |
|---|---|---|---|---|
| 9H | ||||
| Number (%) | 219/246 (89.0) | 27/246 (11.0) | 246 | |
| Completed treatment*, n (%) | 186/219 (84.9) | 26/27 (96.3) | 212 (86.2) | 0.142 |
| Not completed, n (%) | 33/219 (15.1) | 1/27 (3.7) | 34(13.8) | |
| side effects | 9† | 1‡ | 9 | |
| Dropout | 20 | 0 | 20 | |
| stop due to TNF antagonist stop | 4 | 0 | 4 | |
| Duration from LTBI treatment to initiation of TNF antagonist, median (IQR), days | 24 (21–35) | 28 (14–90) | 24 (21–35) | 0.110 |
| Active TB occurrence during follow up | 5/219 (2.3) | 0/27 (0) | 5 | NS |
Data are presented as numbers (percentages) unless otherwise indicated. *Completed Treatment was defined as the ingestion of >80% of all prescribed medications within 43 weeks for 9H or within 16 weeks for 3HR. †Five hepatitis, two active TB during LTBI treatment, one skin rash and one mood change. ‡One skin rash. LTBI, latent tuberculosis infection; H, isoniazid; HR, isoniazid plus rifampicin; TNF, tumor necrosis factor; TB, tuberculosis; NS, not significant.